Patents Assigned to Millennium Pharmaceuticals, Inc.
  • Patent number: 10335494
    Abstract: The present invention relates to methods for the treatment of cancers. In particular, the invention provides methods for treatment of cancer by administering an Aurora kinase inhibitor in combination with an anti-CD30 antibody. The combined administration of the Aurora kinase inhibitor and anti-CD30 antibody can be simultaneous, separate, sequential or consecutive.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: July 2, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Ole Petter Veiby
  • Patent number: 10335411
    Abstract: Disclosed are methods for the treatment of cancer in patients in need of such treatment. The methods comprise administering to such a patient an ubiquitin-activating enzyme (UAE) inhibitor such as ((1R,2R,3S,4R)-2,3-dihydroxy-4-(2-(3-(trifluoromethylthio) phenyl)pyrazolo[1,5-a]pyrimidin-7-ylamino)cyclopentyl)methyl sulfamate (Compound 1) or a pharmaceutically acceptable salt in combination with radiation. Also disclosed are medicaments for use in the treatment of cancer.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: July 2, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Neil Bence, Marc Hyer, Michael Milhollen, Vivek Samnotra, Sergio Luis Santillana Soto, Darshan Sappal
  • Patent number: 10323018
    Abstract: This invention provides compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein T, J, R, R4, Rq, o, RA, W and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, and/or T-cell mediated autoimmune disease.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: June 18, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Brian Scott Freeze, Kenneth M. Gigstad, David A. Janowick, Hong Myung Lee, Zhan Shi, Francois Soucy, Stepan Vyskocil
  • Publication number: 20190117652
    Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering a Raf inhibitor in combination with a taxane. The present disclosure relates to methods of treating a subject suffering from cancer, comprising administering to the subject: (i) a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and (ii) a taxane or a pharmaceutically acceptable salt thereof; the amount of the Raf kinase inhibitor and taxane or a pharmaceutically acceptable salt thereof is such that the combination thereof is therapeutically effective in the treatment of the cancer.
    Type: Application
    Filed: December 22, 2015
    Publication date: April 25, 2019
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Viviana BOZON, Katherine M. GALVIN, Rachael L. BRAKE, Qunli XU, Karuppiah KANNAN
  • Patent number: 10213436
    Abstract: Disclosed are methods for the treatment of various cell proliferative disorders. Disclosed in particular are methods for treatment of various cell proliferative disorders by administering a selective inhibitor of Aurora A kinase in combination with taxane-based chemotherapy, such as paclitaxel or docetaxel.
    Type: Grant
    Filed: September 3, 2015
    Date of Patent: February 26, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Jeffrey A. Ecsedy, Wen Chyi Shyu, Arijit Chakravarty, Robert W. Kleinfield, Kha N. Le, Karthik Venkatakrishnan
  • Patent number: 10202389
    Abstract: Disclosed are chemical entities that inhibit ubiquitin-activating enzyme (UAE), each of which is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein Y is and W, Z, XY, RY1, RY2 and RY3 are defined herein; pharmaceutical compositions comprising the chemical entities; and methods of using the chemical entities. These chemical entities are useful for treating disorders, particularly cell proliferation disorders, including cancers.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: February 12, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Roushan Afroze, Indu T. Bharathan, Jeffrey P. Ciavarri, Paul E. Fleming, Jeffrey L. Gaulin, Mario Girard, Steven P. Langston, Francois Soucy, Tzu-Tshin Wong, Yingchun Ye
  • Patent number: 10202373
    Abstract: The present invention provides a compound of formula I: wherein R1, X1, X2, R2, R3, R4, R5, n, and m are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.
    Type: Grant
    Filed: January 13, 2015
    Date of Patent: February 12, 2019
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Indu T. Bharathan, Chris Blackburn, Jeffrey P. Ciavarri, Jouhara Chouitar, Courtney A. Cullis, Natalie D'Amore, Paul E. Fleming, Kenneth M. Gigstad, Krista E. Gipson, Mario Girard, Yongbo Hu, Janice Lee, Gang Li, Mansoureh Rezaei, Michael D. Sintchak, Francois Soucy, Stephen G. Stroud, Tricia J. Vos, He Xu, Yingchun Ye
  • Publication number: 20190038762
    Abstract: This invention relates to antibody-drug conjugates capable of delivering cytotoxic compounds to cancers expressing the guanylyl cyclase C (GCC) transmembrane cell surface receptor.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 7, 2019
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., IMMUNOGEN, INC.
    Inventors: Ole Petter VEIBY, Ravi V. J. CHARI, John M. LAMBERT, Katharine C. LAI, Robert W. HERBST, Scott A. HILDERBRAND
  • Patent number: 10179124
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: January 15, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan Zhu, Wenrong Huang
  • Publication number: 20180355062
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Application
    Filed: July 6, 2018
    Publication date: December 13, 2018
    Applicants: Millennium Pharmaceuticals, Inc., Amgen British Columbia Inc.
    Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
  • Publication number: 20180346578
    Abstract: Antibody formulations are described comprising a mixture of an anti-a4b7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-a4b7 antibody in vivo.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 6, 2018
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Willow Diluzio, Phuong M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz, Erica Helen Jenkins, Maria Rosario
  • Patent number: 10144742
    Abstract: This invention provides compounds of formula I and subsets thereof: wherein T, J, R, R4, Rq, o, RA, and RB and subsets thereof are as described in the specification. The compounds are inhibitors of NAMPT and are thus useful for treating cancer, inflammatory conditions, or T-cell mediated autoimmune disease.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: December 4, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Kenneth M. Gigstad, David P. Cardin, Takaharu Hirayama, Masaaki Hirose, Yongbo Hu, Hiroyuki Kakei, Hong Myung Lee, Takashi Motoyaji, Noriyuki Nii, Zhan Shi, Stepan Vyskocil, Hiroyuki Watanabe
  • Patent number: 10143752
    Abstract: Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: December 4, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Irving H. Fox, Catherine Scholz
  • Publication number: 20180330043
    Abstract: The present invention provides methods for optimization of the harvest process by clarification of cell samples using centrifugation and depth filtration. The present invention provides methods for the determination of the optimal ratio of Q/? for the centrifugation step of a harvest process of a cell culture. The present invention provides methods for the determination of the number of particles and the size of the particles in the centrate of a centrifugation step of a harvest process of a cell culture by the use of imaging technology. The present invention provides methods for the scaling of the harvesting process from lab-bench scale to industrial scale.
    Type: Application
    Filed: June 4, 2018
    Publication date: November 15, 2018
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Sheldon F. Oppenheim, Kevin C. Carrigan
  • Publication number: 20180327497
    Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Application
    Filed: May 18, 2018
    Publication date: November 15, 2018
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Willow Diluzio, Phuong M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz, Erica Helen Jenkins, Maria Rosario
  • Publication number: 20180311239
    Abstract: Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra?, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    Type: Application
    Filed: March 16, 2018
    Publication date: November 1, 2018
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Matthew O. DUFFEY, Dylan ENGLAND, Brian Scott FREEZE, Zhigen HU, Steven LANGSTON, Charles McINTYRE, Hirotake MIZUTANI, Koji ONO, He XU
  • Publication number: 20180290983
    Abstract: Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.
    Type: Application
    Filed: November 9, 2017
    Publication date: October 11, 2018
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ashley Sue MCCARRON, Todd B. SELLS, Matthew STIRLING, Stephen G. STROUD
  • Publication number: 20180289811
    Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.
    Type: Application
    Filed: June 21, 2018
    Publication date: October 11, 2018
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Irving H. Fox, Catherine Scholz
  • Publication number: 20180271996
    Abstract: Disclose herein are combinations comprising HER2-targeted antibody-drug conjugates and immune checkpoint inhibitors and methods of using such combinations in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: February 27, 2018
    Publication date: September 27, 2018
    Applicants: Mersana Therapeutics, Inc., Millennium Pharmaceuticals Inc.
    Inventors: Natalya D. BODYAK, Donald A. BERGSTROM, Marc HYER, Timothy B. LOWINGER, Marina PROTOPOPOVA, Ole Petter VEIBY, Aleksandr V. YURKOVETSKIY, Qing Xiu ZHANG
  • Publication number: 20180263979
    Abstract: The present disclosure relates to methods for the treatment of cancers. In particular, the disclosure provides methods for treatment of cancer by administering Raf inhibitors in combination with Aurora kinase inhibitors. The present disclosure relates to methods of treating subject suffering from cancer, comprising administering to the subject a Raf kinase inhibitor or a pharmaceutically acceptable salt thereof; and an Aurora kinase inhibitor or a pharmaceutically acceptable salt thereof; the amount of said Raf kinase inhibitor or a pharmaceutically acceptable salt thereof being such that the combination thereof is therapeutically effective in the treatment of the cancer. In some [embodiments, the cancer is a solid tumor cancer.
    Type: Application
    Filed: December 22, 2015
    Publication date: September 20, 2018
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Viviana BOZON, Katherine M. GALVIN